Navigation Links
VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Abstract #2209-PO, Evaluation of Glycemic Parameters in Obese Diabetic Patients Treated with Phentermine and Topiramate: Outcomes in a Private Practice Setting has been published in the American Diabetes Association 2007 Scientific Sessions Abstract book. The abstract is available on the American Diabetes Association website.

The purpose of analyzing these data compiled from Dr. Najarian's private medical practice was to evaluate the glycemic effects of topiramate plus phentermine in type 2 diabetic patients with metabolic co-morbidities. The abstract was based on a series of consecutive obese type 2 diabetic patients that had both baseline and on-treatment HbA1c measurements. The results showed that topiramate plus phentermine reduced HbA1c levels and the need for other anti-diabetic medications. Metabolic co-morbidities were also reduced.

About Dr. Najarian

Thomas Najarian, M.D., a Board Certified Specialist in Internal Medicine, is a graduate of MIT (SB, SM in Mechanical Engineering) and Harvard Medical School. He is a former faculty member of the Harvard Medical School. Dr. Najarian was the former Medical Director and Vice-President of Medical Affairs at Interneuron Pharmaceuticals (now Indevus Pharmaceuticals). He is the author of many scientific publications as well as the holder of several U.S. and international patents. Dr. Najarian has 25 years experience in treating obesity and discovered the proprietary combination of topiramate plus phentermine for the treatment of obesity and related conditions. In 2001, VIVUS in-licensed Dr. Najarian's invention and intellectual property associated therewith in exchange for certain milestone payments, stock options and future royalty payments based
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/30/2009)...MIDLOTHIAN, Va., June 30 In two re...lus nebulizer and PRONEB compressors (Ultra and Ul...l fumarate (Perforomist, DEY LP, Mylan Inc.) impro...at researchers chose PARI products as the exclusiv...aintenance treatments for COPD. Sutherland et al....
(Date:6/30/2009)...SAN DIEGO, June 30 Calixa Therapeu...e 2 clinical trial of CXA-101 in patients with com...ew broad-spectrum, parenteral cephalosporin antibi...ity against Pseudomonas aeruginosa , including dr...A-101 as a potential treatment for serious bacteri...
(Date:6/29/2009)...ROCHESTER, Minn., June 29 /PRNewswire-USNewswire/ ...he effectiveness of deep brain stimulation (DBS)...ve disorder (OCD) and Tourette,s syndrome are unde... according to a review in the June 2009 issue of ...ation has long been seen as valuable for controlli...
(Date:6/29/2009)... SOUTHAMPTON, England, June 29 ...ompany developing novel, small molecule drugs,tar...es positive results from,a Phase IIa clinical tri...nocturia. The trial showed that oral VA106483 was ...ed anti-diuretic effect in patients, as determined...
Breaking Medicine Technology:PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 2Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 3Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Schering Plough Receives Clearance From U S Federal Trade Commission for Planned Acquisition of Organon Biosciences N V 6490 1Schering Plough Receives Clearance From U S Federal Trade Commission for Planned Acquisition of Organon Biosciences N V 6490 2Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 6488 1Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 6488 2Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 6488 3Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 6488 4National Council on Disability 28NCD 29 Hosts Quarterly Meeting 6486 1National Council on Disability 28NCD 29 Hosts Quarterly Meeting 6486 2National Council on Disability 28NCD 29 Hosts Quarterly Meeting 6486 3In Progressive Move 21st Services Forms Independent Medical Advisory Board to Study Longevity Mortality Risk 6484 1In Progressive Move 21st Services Forms Independent Medical Advisory Board to Study Longevity Mortality Risk 6484 2
...epressed people with bipolar,disorder who are taki...ication is no more effective than a placebo (sugar...arch 28, 2007 in the New,England Journal of Medici...-site Systematic Treatment Enhancement Program,for...cal trial,funded by the National Institutes of Hea...
...s Utility in Evaluating Drug,Efficacy; Dr. H. Brya...apy , ,PLEASANTON, CA, Mar 30, 2007 (MARKET WIRE v...ASDAQ: LIPD) Dr. H. Bryan Brewer, Jr.,Chief Scien...from,the wide range of presentations at the recent...ew Orleans that the rationale for HDL,being the ne...
Other Medicine Technology:Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 2Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5
(Date:7/3/2009)...he health care reform details emerge, more entrepr...all groups and business insurance premiums. Now, t...bsites such as the Small Business Health Insurance... Minneapolis, Minn. (PRWEB) July 3, 2009 -- Th...the House, which has entrepreneurs worried about h...
(Date:7/2/2009)...ers to Support Principles to Govern Health Insurer...swire-USNewswire/ -- Nearly nine out of ten voters...e too much influence over how doctors care for the...ort the concept of a "Health Insurer Code of Condu...les for health insurance companies with respect to...
(Date:7/2/2009)...PRNewswire-USNewswire/ -- Acetaminophen is an ingr...tion medicines to help relieve pain and reduce fev... name, Tylenol and prescription brand names, Vicod... the FDA met on June 30, 2009 to address liver rel...e committee voted 20-17 to urge the FDA to put a b...
(Date:7/2/2009)...2 Dr Daniel Goldberg, a leading Ne...dy to measure the effectiveness of using 5% Betadi...on, worldwide, highly contagious and often severe ... term visual impairment due to corneal involvement...ited to register to participate in the Betadine fo...
Breaking Medicine News(10 mins):Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 2Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2
...s been appointed honorary consultant and adviser t...peciality of plastic, hand and reconstructive micr... Department of surgery in Ganga Medical Centre and...on and perform major operations to members of arme...
...cancer which has very poor prognosis. This is main...ad in the body//. The spread of cancer cells in th...be very fatal in case of cancer patients as it blo...s in early death. Hence early detection and treat...
...mes to their bowel cancer screening test? This is .../ of the first Australian national bowel cancer sc...ng the benefits and harms of alternate screening m...ded not to offer consumers a choice of screening t...
...ve smoking worsens allergies.The study, entitled “...ates// allergic airway disease in human beings” ca...urnal of Allergy and Clinical Immunology (JACI) We... the peer-reviewed journal of the American Academy...
Other Medicine News:Health News:IMP3 the Novel Biomarker for Metastatic Cancer 2Health News:IMP3 the Novel Biomarker for Metastatic Cancer 3Health News:Choosing your Bowel Cancer Test 2Health News:Passive Smoking Worsens Allergies 2
... products are offered as 1-piece or modular, in re...ts may be customized with handles of choice and ot... ports. Many standard patterns are available from ... delivery times. , Please Note: Individual instr...
... products are offered as 1-piece or modular, in re...ts may be customized with handles of choice and ot... ports. Many standard patterns are available from ... delivery times. , Please Note: Individual instr...
... products are offered as 1-piece or modular, in re...ts may be customized with handles of choice and ot... ports. Many standard patterns are available from ... delivery times. , Please Note: Individual instr...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: